Trichomoniasis

Summary

Trichomoniasis (MONDO:0002154) is a disease (an umbrella term covering 5 Mondo subtypes) and 16 clinical trials. Top therapeutic interventions include metronidazole, secnidazole, and tinidazole. A subtype of protozoa infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	trichomoniasis
Mondo ID	MONDO:0002154
MeSH	D014245
DOID	DOID:1947
ICD-10-CM	A59
ICD-11	1220564554
NCIT	C35720
SNOMED CT	56335008
UMLS	C0040921
MedGen	52838
Is cancer (heuristic)	no

Also known as: infections, Trichomonas · Trichomonas infection

Disease family

This is a subtype of protozoa infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › trichomoniasis

Related subtypes (14): primary amebic meningoencephalitis, granulomatous amebic encephalitis, trypanosomiasis, giardiasis, protozoal dysentery, malaria, Acanthamoeba keratitis, amebiasis, babesiosis, balantidiasis, coccidiosis, theileriasis, leishmaniasis, dientamoebiasis

Subtypes (5): Trichomonas vaginitis urogenital infection, Trichomonas prostatitis, Trichomonas balanoposthitis, Trichomonas cervicitis, Trichomonas tenax infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Metronidazole	Approved (phase 4)
Secnidazole	Approved (phase 4)
Tinidazole	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE2	2
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01018095	PHASE4	COMPLETED	Trichomonas Vaginalis Recurrence Among HIV+ Women
NCT03935217	PHASE3	COMPLETED	A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
NCT01230814	PHASE2	COMPLETED	Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
NCT01439503	PHASE2	COMPLETED	Safer Sex Program for Young African-American Men
NCT01591889	PHASE1	COMPLETED	Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
NCT06951438	Not specified	RECRUITING	Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision
NCT07082127	Not specified	NOT_YET_RECRUITING	Endosymbionts in Trichomonas Vaginalis Pathogenicity
NCT00334555	Not specified	COMPLETED	Control of Trichomoniasis
NCT00998530	Not specified	COMPLETED	Trichomoniasis: Genotype and Phenotype Correlations in African American Women
NCT01728103	Not specified	TERMINATED	Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays
NCT02203942	Not specified	COMPLETED	Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis
NCT03596151	Not specified	TERMINATED	Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs
NCT03852316	Not specified	COMPLETED	Clinical Study of a Diagnostic Device for NG, TV and CT in Women
NCT04098900	Not specified	COMPLETED	Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women
NCT05541081	Not specified	COMPLETED	Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe
NCT06566677	Not specified	COMPLETED	Point of Care Rapid STI Test Optimization and Validation Extension

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METRONIDAZOLE	4	1
SECNIDAZOLE	4	1
TINIDAZOLE	4	1